Reno, Nevada--(ACN Newswire via SeaPRwire.com - March 24, 2026) - Scandium Mining Corp. (TSXV: SCY) (OTC PINK: SCYYF) ("Scandium International" or the "Company"), a leader in the advancement of critical mineral resources, is pleased to announce the release of its updated investor presentation, now available to investors and stakeholders. The new presentation can be accessed here: Investor PresentationThe new investor presentation provides updated information on the Nyngan project in New South Wales, Australia, which is now fully shovel-ready. This project is one of only two primary scandium deposits at this advanced stage in the western world, positioning the company at the forefront of the emerging scandium market.Scandium is an essential element in high-performance applications, including aerospace, defense, and clean power generation. Its unique properties-such as exceptional strength-to-weight ratio and improved corrosion resistance when alloyed with aluminum-make it indispensable for the next generation of lightweight, durable materials. As demand grows for advanced technologies and sustainable solutions, scandium's role is increasingly being recognized by innovative manufacturers and governments alike."We're excited to share this comprehensive update on our progress," said Peter Evensen, CEO of Scandium International. "With our mining license now valid over the entire resource, the project is shovel-ready and we are uniquely positioned to supply scandium at scale to industries that are shaping the future."To view the latest presentation and learn more about Scandium Mining's plans, visit: Scandium International Mining CorporationAbout Scandium MiningScandium Mining is dedicated to unlocking the potential of scandium for high-impact industries worldwide. With its shovel-ready primary scandium deposit, the company is committed to responsible development and long-term value creation.For inquiries to Scandium International Mining Corp, please contact: Peter Evensen, President and CEOTel: (775) 355-9500Harry de Jonge (Controller)Tel: (702) 703-0178Email: info@scandiummining.comCautionary Note Regarding Forward-Looking InformationThis news release includes certain information that may be deemed "forward-looking information". Forward-looking information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "believe", "continue", "plans" or similar terminology, or negative connotations thereof. All information in this release, other than information of historical facts, general future plans and objectives for the Company and the Nyngan Scandium Project, are forward-looking information that involve various risks and uncertainties. Although the Company believes that the expectations expressed in such forward-looking information are based on reasonable assumptions, such expectations are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking information.For more information on the Company and the key assumptions, risks and challenges with respect to the forward-looking information discussed herein, and about our business in general, investors should review the Company's most recently filed annual information form, and other continuous disclosure filings which are available at www.scandiummining.com Readers are cautioned not to place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289611 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 国际指数评级机构明晟 MSCI日前公布了年度 ESG（环境、社会及企业管治） 评级报告，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK））评级从"A"级跃升至最高"AAA"级。公司在负责任投资、可持续融资业务、人力资本发展、数据安全及企业行为等领域表现尤为突出，处于全球同业领先水平。这一重要突破标志着公司在可持续发展领域的持续努力与卓越表现获得国际权威机构的高度认可。根据MSCI ESG评级的最新评估，国泰君安国际在多个关键议题上表现优异，成为本次评级上调的主要驱动因素：在负责任投资方面，得益于可持续发展指标的优化调整，公司得分显著提升。公司始终致力于可持续发展，将负责任的投资理念全面融入投资组合管理，在投资流程中系统性地纳入ESG因素，以此在传统财务分析基础上，进一步增强对潜在投资的ESG表现评估，从而推动被投资方的绿色转型。在可持续融资业务方面，国泰君安国际在投资银行业务中积极开展可持续发展尽职调查，并通过为企业客户承销及发行绿色债券，持续推动绿色金融发展，降低与业务相关的环境风险，展现了其在绿色投融资领域的责任担当与专业能力。在人力资本发展方面，由于绩效评估方法论的改进以及公司实践的持续完善，得分亦实现增长。公司秉持"人才是第一资源"的经营理念，并奉行"以人为本、协同协作"的原则，视员工为本集团最有价值的资产。通过提升薪酬待遇、提供员工福利、创造成长机会，持续加强人才招募和留任策略，进一步巩固公司作为优选雇主的地位，推动长期可持续发展。在数据安全领域，MSCI报告指出，国泰君安国际主要运营于香港这一隐私保护法规较为严格的地区，公司在数据安全实践方面保持行业领先，通过制定覆盖全集团的隐私政策，并引入外部独立IT安全审计，公司有效构筑了网络安全风险防线。国泰君安国际此次MSCI ESG评级跃升至AAA级，充分体现了公司在环境、社会及管治方面的长期投入与系统化建设成果。作为国泰海通集团的重要国际业务平台，公司将继续秉持可持续发展理念，深化ESG治理实践，积极履行社会责任，为股东、客户及社会创造长期可持续价值。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"AAA"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Baguio Green Group Limited (‘‘Baguio’’ or the ‘‘Group’’, Stock Code: 01397.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the Year, the Group’s revenue amounted to approximately HK$2,424.6 million, representing a decrease of approximately 6.9% as compared to the same period last year. Profit for the Year amounted to approximately HK$97.1 million, representing an increase of approximately 72.0% as compared to the same period last year. The Board recommends the payment of a final dividend for the Year at HK7.0 cents per share.Business Overview and ProspectsDuring the Year, revenue from cleaning services as the Group’s core business amounted to approximately HK$1,896.5 million, accounting for approximately 78.2% of the Group’s total revenue. The Group’s cleaning services cover various scenarios, including for Government streets, markets, police stations, fire stations, leisure venues, hospitals and clinics. In addition, the Group provides cleaning services for numerous different places such as universities, large exhibition centers, Hong Kong International Airport, housing estates and private institutions.During the Year, the Group successfully awarded a 3-year contract from the Marine Department of the Government for approximately HK$150 million for the provision of “Marine Refuse Cleansing and Disposal Services in the Eastern waters of Hong Kong”. This contract marks a significant milestone for Baguio, as it represents a strategic expansion of its service portfolio from land to sea, further strengthening its leading position in Hong Kong’s integrated environmental services market. Under the contract, Baguio delivers comprehensive marine refuse cleansing and ship refuse collection services in the Eastern waters of Hong Kong starting from 1 October 2025 including, but not limited to: Victoria Harbour, Central, Sheung Wan, Causeway Bay, Tsim Sha Tsui, Yau Ma Tei, Cheung Sha Wan, Shau Kei Wan, Kwun Tong, Sai Kung, Tolo Harbour and Tai Po. Winning this contract signifies strong market recognition of Baguio’s outstanding performance over the past 46 years. The Group will seamlessly extend its professional standards and operational efficiency in land-based waste management to the marine environment, striving to safeguard Hong Kong’s valuable marine ecosystem and present a cleaner, more beautiful Victoria Harbour to both residents and tourists.Waste management and recycling business recorded revenue of approximately HK$277.8 million, accounting for approximately 11.5% of the Group’s total revenue. The gross profit margin of the waste management and recycling business increased from 11.6% for the same period last year to 15.0%, driving the gross profit of this business up by approximately 25.2% to approximately HK$41.9 million, mainly due to the Government’s proactive promotion of recycling and the substantial expansion of the network of recycling spots, including those for food waste, which facilitated public participation and effectively stimulated collection, and the contribution from the green technology business.The Group continued to provide Government-related waste collection services to five districts, serving a population of approximately 1.6 million.In terms of recycling, the Group is contracted by the Environmental Protection Department (“EPD”) of the Government to provide collection services for thousands of recycling spots (including plastics, glass bottles, metals, waste paper and food waste) across Hong Kong. During the Year, the Group provided collection services for recycling bins in public places and schools. Baguio also provides collection services for Recycling Stations of “GREEN@COMMUNITY”, recycling stores and smart recycling machines, and other institutions in Hong Kong. In addition, Baguio also provides the Government with glass bottles collection and management services and food waste collection services in several districts in Hong Kong, and is one of the market leaders. In addition, during the Year, the Group was successfully awarded two 35-month contracts from the EPD, with a total value of approximately HK$43 million. During the Year, the Group was responsible for operating the “GREEN@Tai Wo” and “GREEN@Po Lam” recycling stores, and collaborated with nearby buildings, organizations, and community stakeholders to establish and operate fixed and mobile recycling spots for waste collection, provide community recycling support to facilitate citizens, and promote and educate the public on waste sorting and recycling in the community to strengthen citizens’ recycling habits.As a leading environmental services provider in Hong Kong, the Group provides integrated environmental management solutions including waste management, smart recycling and professional landscaping services to Kai Tak Sports Park, which hosts major sports events and concerts. With excellent environmental protection technologies and experience in operating large-scale international venues, the Group has fully demonstrated its strength in undertaking large-scale international programmes and delivering high-quality services. During the Year, the Group also provided waste recycling services for various Lunar New Year fairs across Hong Kong Island, Kowloon and the New Territories.Regarding green technology business, the Group won a new contract in relation to the development and supply of a new generation of solar-powered compacting refuse bins to the Government. This innovative product is designed with an auto-sensing inlet and indicator lights, and under its sealed design, it is equipped with devices for ventilation, lighting, and deodorization. Meanwhile, it is equipped with a big data platform and wireless technology to monitor data in real time, enabling effective tracking of the status of waste collection points, strategic deployment of resources, optimization of operational efficiency, and enhanced planning for future initiatives. Furthermore, the solar-powered compacting refuse bins adopt solar panels and rely on renewable energy, which significantly reduces carbon emissions. They can be flexibly deployed in various scenarios, suitable for remote areas where there are no refuse collection points. This product is expected to be gradually launched into the market in 2026.The Group seizes the opportunity of smart city development and has been committed to expanding its market share of smart recycling in recent years. Currently, Baguio’s smart recycling products, such as smart recycling machines, smart food waste recycling machines, and smart balances, have been deployed in different places across Hong Kong, including Government venues and schools, private housing estates, commercial buildings, theme parks, large-scale exhibition venues, and sports stadiums. These products provide the public with convenient recycling services 24 hours a day and help increase Hong Kong’s overall recycling volume.In partnership with Jardine Engineering Corporation Limited, the Pilot Biochar Production Plant at the EcoPark in Tuen Mun converts yard waste into high-quality biochar with pyrolysis technology for various applications, the production plant effectively “turns waste into useful resources”.As for the landscaping business, the Group provides landscaping services for a wide range of clients, including large private residences, Government premises, schools, shopping malls, hotels, Hong Kong Housing Authority, Hospital Authority, Hong Kong Jockey Club, Hong Kong Science Park, the University of Hong Kong, Hong Kong University of Science and Technology, Hong Kong Wetland Park, as well as 33 sports turf venues under the Leisure and Cultural Services Department, etc. During the Year, the Group provided landscaping services for Kai Tak Sports Park, Hong Kong International Airport, Hong Kong-Shenzhen Innovation and Technology Park, Nano Parks, the Tung Chung New Town Extension (West), Hung Shui Kiu/Ha Tsuen New Development Area and the ventilation building at the eastern portal of the Tseung Kwan O – Lam Tin Tunnel.For pest management business, the Group provided pest management services for venues in the Tsuen Wan District during the Year. In addition, the Group provided pest and rodent control services for hospitals, clinics and the headquarters of the Kowloon East, Kowloon Central and Kowloon West Clusters under the Hospital Authority. The Group also continued to provide termite control and monitoring services for 24 temples under the Chinese Temples Committee.The Promotion of Recycling and Proper Disposal of Products (Miscellaneous Amendments) Bill 2025 submitted by the Government was passed by the Legislative Council during the Year. This bill establishes a common legal framework for producer responsibility scheme applicable to different products. Under this framework, the Government plans to submit the producer responsibility scheme on plastic beverage containers and beverage cartons in 2026. The scheme encourages citizens to return used containers for recycling to earn rebate, which will help significantly increase the recycling rate. Benefiting from the scheme, Baguio’s recycling volume is expected to be directly driven up, providing attractive returns for the Group’s long-term investments in recycling services and competitive barriers.The Government is actively developing the Northern Metropolis. Four new development areas include Kwu Tung North/ Fanling North, Hung Shui Kiu/Ha Tsuen, Yuen Long South, and San Tin Technopole are under construction. The Government has resumed more than 400 hectares of private land within these four new development areas, completed land levelling for 80 hectares, and is progressively handing over these lands to relevant departments for building road and railway infrastructure, public and private housing, schools, public markets, ecological conservation, as well as development of innovation and technology industry. The Group believes that this will bring opportunities for many of its core businesses.Looking forward, the Group will continue to increase the market share of its core businesses and proactively engage in expansion in Hong Kong and beyond. Meanwhile, in line with the development of the Group, it will actively explore potential mergers and acquisitions, joint ventures or new business projects to accelerate future business growth and deliver substantial and long-term returns to shareholders.For details of the Group's 2025 annual results announcement, please visit the following website: https://www.baguio.com.hk/en/investor/notices/About Baguio Green GroupEstablished in 1980, Baguio Green Group (Stock code: 01397.HK) is one of Hong Kong’s largest integrated environmental management solution providers. It provides a full spectrum of professional services including professional cleaning, waste collection & recycling, waste management, green technology, green products, horticulture & landscaping, and pest control. The Group delivers innovative environmental solutions using the latest technologies to serve a wide range of customers in various sectors including Government departments, statutory organizations and multinational corporations. Fully committed to ESG, the Group works relentlessly to advance sustainable development and create a cleaner, greener, healthier city for a greener tomorrow. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 碧瑶绿色集团有限公司 （"碧瑶"或"集团"；股份编号：01397.HK）欣然宣布截至2025年12月31日止年度（"年内"）之全年业绩。年内，集团收益约为24.2亿港元，较去年同期减少约6.9%。年内纯利约为9,700万港元，较去年同期增加约72.0%。董事会建议派付本年度的末期股息每股7.0港仙。业务回顾及展望年内，清洁作为集团的核心业务，收益约19.0亿港元，占集团总收益约78.2%。集团的清洁服务涵盖不同场景，包括为政府辖下街道、街市、警局、消防局、康乐场地、医院及诊所提供清洁服务。此外，集团亦为大学、大型展览中心、香港国际机场、屋苑及私人机构等众多不同场所提供清洁服务。集团于年内成功中标政府海事处一份为期三年总值约1.5亿港元的"香港东部水域海上垃圾清理及处理服务"合约。此合约标志着碧瑶的服务版图，成功由陆地策略性拓展至海洋，为集团业务发展的重要里程碑，进一步巩固其在香港综合环境服务市场的领导地位。根据合约，碧瑶自2025年10月1日起，于香港东部水域包括但不限于维多利亚港、中环、上环、铜锣湾、尖沙咀、油麻地、长沙湾、筲箕湾、观塘、西贡、吐露港及大埔等地区，提供全面的海上清洁及船只生活垃圾收集服务。获得此合约，代表市场充份肯定碧瑶成立46年来的卓越表现。集团将其陆上废物管理的专业标准与营运效率无缝延伸至海上，致力守护香港珍贵的海洋生态环境，为市民及旅客呈现一个更洁净、更美丽的维多利亚港。废物管理及回收业务于年内收益为约2.8亿港元，占集团总收益约11.5%。废物管理及回收业务的毛利率由去年同期11.6%，增加至15.0%，拉动该业务毛利上升约25.2%，至约4,200万港元，主要受惠于政府积极推动回收，大幅扩展包括厨余的回收点网络，便利市民参与并有效刺激收集量，及绿色科技业务所带动。集团继续为政府辖下的五区提供废物收集服务，服务人口约160万。回收方面，集团作为政府环境保护署（"环保署"）服务承办商，为香港数千个回收点提供收集服务（包括塑料、玻璃樽、金属、废纸及厨余）。集团于年内为公共场所及学校的回收箱提供收集服务。此外，碧瑶亦为香港众多"绿在区区"回收环保站、回收便利点、智能回收机及不同机构提供回收服务。另外，碧瑶为政府于香港多区负责玻璃容器收集及处理，以及厨余收集，为市场领导者之一。此外，集团于年内成功中标环保署两份为期35个月总值港币约4,300万港元的合约。年内，集团负责营运「绿在太和」及「绿在宝琳」的回收便利点，以及与邻近大厦、机构及小区持份者合作，建立及营运固定及流动回收点进行收集，提供便利市民的小区回收支持，以及在小区推动和教育市民分类回收，强化市民回收习惯。集团作为香港领先的环境服务龙头，为专门举办大型体育赛事及演唱会的启德体育园，提供废物管理、智能回收及专业园艺工程的综合环境管理解决方案。凭借卓越的环保技术与大型国际场馆营运经验，充分展示了集团在承接国际级大型项目及高规格服务方面的实力。年内，集团更为香港、九龙及新界等多个年宵市场提供废物回收服务。绿色科技业务方面，集团赢得新合约，为政府研发及供应新一代太阳能废物压缩箱。此创新产品设计具有自动感应投入口及指示灯，在密封式设计下加装通风、照明及除臭等装置。同时配备大数据平台及无线技术实时监控数据，有效追踪废物收集点的状态，策略地部署资源，优化运作效率，并加强对未来措施的规划。此外，太阳能废物压缩箱采用光伏板，依靠可再生能源，大大减低碳排放，可灵活配置于不同场景，适合没有垃圾收集站的偏远地区。此产品预计于2026年陆续推出市场。集团把握智慧城市发展的契机，近年致力扩大智能回收的市场份额。目前碧瑶智能回收产品，例如：智能回收机、智能厨余回收机及智能磅等已遍及香港不同角落，包括各政府场地及学校、私人屋苑、商业大厦、主题乐园、大型展覧及体育场馆等。每日24小时为市民提供便捷的回收体验，并有助提升香港整体回收量。集团与怡和机器有限公司合作位于香港屯门环保园的生物炭工厂通过热解技术将园林废料转化为高质量生物炭以作各种应用，从而达到"转废为材"的目的。园艺方面，客户涵盖大型私人住宅、政府处所、学校、商场、酒店、香港房屋委员会、香港医院管理局、香港赛马会、香港科学园、香港大学、香港科技大学、香港湿地公园及康乐及文化事务署辖下33个运动草地场地提供草地护养人员服务等。集团年内为启德体育园、香港国际机场、港深创新及科技园、微型公园、东涌西新发展区、洪水桥╱厦村新发展区和将蓝隧道东面排风口大楼提供园艺工程。虫害管理方面，集团年内为荃湾区政府辖下场地提供虫害管理服务。此外，集团为医管局辖下九龙东、九龙中及九龙西联网各医院诊所及总部提供灭虫灭鼠服务，同时继续为华人庙宇委员会辖下24间庙宇，提供白蚁防治及监测服务。政府提交的《2025年促进循环再造及妥善处置产品（杂项修订）条例草案》于年内获立法会通过，为生产者责任计划订立适用于不同产品的共同法律框架。在此框架下，政府计划于2026年提交有关塑料饮料容器及纸包饮品盒生产者责任计划。此计划鼓励市民将使用完的容器交回作循环再造，从而获取回赠，有助大大增加回收率。受益于该计划，预计将直接拉动碧瑶的回收量，为集团多年来于回收服务建设的投资及竞争壁垒，提供吸引回报。政府正全速发展北部都会区，其中四个新发展区，包括古洞北╱粉岭北、洪水桥╱厦村、元朗南及新田科技城已进入施工阶段。政府已经在四个新发展区收回逾400公顷私人土地，完成平整80公顷土地并陆续将这些土地交付部门兴建道路铁路基建、公私营房屋、学校、公众街市、生态保育，以至发展创科产业，相信将为集团多个核心业务带来契机。展望未来，集团在致力提高各核心业务的市场份额的同时，将积极于香港及以外地区扩张。同时因应集团的发展，适时寻找潜在的并购、合营、或新业务项目，加速未来业务增长，为股东缔造可观及长远回报。有关集团2025年度业绩公告详情，请浏览以下网址：https://www.baguio.com.hk/zh-hant/investor/notices/碧瑶绿色集团简介碧瑶绿色集团（股份代号：01397.HK）成立于 1980 年，为香港最大的综合环境管理方案供货商之一，提供环卫保洁、资源回收、循环再造、废物管理、绿色科技、绿色产品、园艺绿化工程及害虫防治等。集团应用最新科技，提供创新环境解决方案，为不同领域的客户提供服务，包括政府部门、各大机构及跨国企业。集团努力不懈地提升环境、社会及管治（ESG）的表现，以推进集团的可持续发展，为了更绿的明天，实现将香港推动成为更清洁、更绿色、更健康城市的愿景。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 今日，国泰海通集团下属公司国泰君安国际控股有限公司（"国泰君安国际"或"公司"，股份代号：1788.HK）作为联席保荐人、保荐人兼整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人，成功助力浙江凯乐士科技集团股份有限公司（"凯乐士科技"，股份代号：2729. HK）在香港联交所主板上市，充分彰显国泰海通集团在跨境资本运作、高效整合资源、服务专精特新科技企业方面的综合实力。（国泰君安国际投行团队出席上市仪式）作为综合智能场内物流机器人龙头企业，凯乐士科技业务横跨29个不同行业及境内外19个国家及地区，两次获得国家工业和信息化部授予的国家级专精特新"小巨人"企业认证。本次发行最终定价为每股16.66港元，总发售股数达3,679.80万股，发行规模6.13亿港元。国际配售和香港公开发售录得踊跃认购，国际配售认购倍数达3.37倍，香港公开发售认购倍数达2153.26倍，充分展现了国际资本对中国高端制造的坚定信心，也生动展示了国泰海通服务科技创新与产业升级的成果。凯乐士科技的成功上市，是继龙旗科技（股票代码：9611.HK）、爱芯元智（股票代码：0600.HK）后，国泰君安国际在今年完成的第三个科技创新领域保荐项目，彰显了国泰君安国际作为一流投行的综合实力与卓越执行力。依托与总部国泰海通的协同优势，公司不仅展现出在复杂跨境资本运作中高效整合资源、精准把握市场窗口的专业能力，更凭借对"专精特新"及高端制造领域的深刻洞察，持续为中国科技企业走向国际资本市场搭建坚实桥梁。展望未来，国泰君安国际将继续秉持金融服务实体经济的初心，以更高水平的综合金融服务，助力更多中国优质企业扬帆远航，在全球资本市场书写新的篇章。关于凯乐士科技凯乐士科技是领先综合智能场内物流机器人提供商，拥有广泛的机器人技术能力及多元化的自主研发机器人产品组合，涵盖广泛采用的高度和有效载荷规格的核心场内物流功能。凯乐士科技在极窄巷道自主移动机器人及四向穿梭车等主要类别的尖端智能场内物流机器人的出货量处于领先地位。凯乐士业务横跨29个不同行业及境内外19个国家及地区，并且成功交付实施了超过1,600个项目，其下游客户涵盖各行各业的领先企业，包括医药、3C电子产品、新能源及汽车行业的领先企业。凭借立足中国，全球领先的长期战略，凯乐士科技将持续受益于中国企业出海的浪潮，成为中国企业出海的关键场内物流基础设施推动者。关于国泰君安国际国泰海通集团下属公司国泰君安国际（股票代号：1788.HK）,是中国证券公司国际化的先行者和引领者，公司是首家通过IPO于香港联合交易所主板上市的中资证券公司。国泰君安国际以香港为业务基地，并在新加坡、越南和澳门设立子公司，业务覆盖全球主要市场，为客户境外资产配置提供高品质、多元化的综合性金融服务，核心业务包括财富管理、机构投资者服务、企业融资服务、投资管理等。目前，国泰君安国际已分别获得穆迪和标准普尔授予"Baa2"及"BBB+"长期发行人评级，MSCI ESG"AAA"评级, Wind ESG"A"评级及商道融绿ESG"A"评级，同时其标普全球ESG评分领先全球81%同业。公司控股股东国泰海通证券（股票代号：601211.SH/2611.HK）为中国资本市场长期、持续、全面领先的综合金融服务商。更多关于国泰君安国际的资讯请见:https://www.gtjai.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

West Palm Beach, FL, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - Global Polo, the entertainment subsidiary of USPA Global, continues its historic relationship with ESPN to showcase the sport of polo, which has expanded its reach to millions of households worldwide. The landmark relationship includes legendary ESPN commentator Chris Fowler hosting the USPA Gold Cup® Final on Mar. 29 for the first time, and the U.S. Open Polo Championship® Final on Apr. 26 for the second year, at the USPA National Polo Center in Palm Beach County, Florida, alongside veteran broadcasters Kenny Rice and Polo Hall-of-Famer Adam Snow.Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco"I've had the privilege of covering some of the most iconic events in sports, and what continues to draw me back to the sport of polo is the unique partnership between the polo player and polo pony, as well as the speed and intensity of competition at the highest level," said Fowler. "Hosting both the USPA Gold Cup and the U.S. Open Polo Championship allows me to share the energy and uniqueness of this beautiful sport with a broader ESPN audience.""There's nothing quite like seeing these world-class athletes and their equine partners compete in such a fast-paced, strategic game," Fowler added.The USPA Gold Cup, first played in 1974, is the second most important tournament in American polo, right next to the U.S. Open Polo Championship, which was first played in 1904. This year's competition will feature 10 elite teams competing at the highest level of the sport from March 4 - 29. The prestigious U.S. Open Polo Championship, played April 1 - 26, is widely recognized as a showcase for many of the world's top players and equine athletes and remains one of the most prestigious polo tournaments globally. Both tournaments have been played back-to-back since they arrived in Palm Beach County, Florida, in 2004. These highly rated polo competitions take place on the U.S. Polo Assn. Stadium Field One at the USPA National Polo Center (NPC) in Wellington, Florida.Coverage of the USPA Gold Cup final in early April, followed by the U.S. Open Polo Championship final match in May, will be available on multiple ESPN platforms, including ESPN2. Check your local listings for specific airtimes."Our long-term relationship with ESPN continues to elevate the sport of polo, the U.S. Polo Assn. brand, and the global momentum behind it," said J. Michael Prince, President and CEO of USPA Global, the company that manages the multi-billion-dollar global sport brand, U.S. Polo Assn. "Chris Fowler's return and expanded presence hosting both the USPA Gold Cup and the U.S. Open Polo Championship further strengthens the momentum and visibility of these world-class tournaments to a global audience.""Supported by ESPN, the sport of polo continues to garner interest from fans around the world," added Prince.Beyond live game coverage, ESPN platforms also feature new episodes of the two-time award-winning show, Breakaway: Presented by U.S. Polo Assn. produced by Global Polo. Viewers can follow exclusive behind-the-scenes coverage, player features, and championship highlights on Global Polo's YouTube channel, including special coverage tied to the USPA Gold Cup and the U.S. Open Polo Championship broadcasts."The United States Polo Association is delighted to see the continued growth of the sport through our relationship with ESPN," said Stewart Armstrong, Chairman of the United States Polo Association (USPA). "The USPA Gold Cup and the U.S. Open Polo Championship represent the highest level of competition at the USPA National Polo Center for the American season, and the increased visibility provided by ESPN underscores the athleticism, dedication, and tradition that define our sport."For the most up-to-date information and breaking news, sign up for the Polo Insider newsletter at globalpolo.com and visit uspolo.org.About ESPNESPN, the world's leading multiplatform sports entertainment brand, features seven U.S. television networks, the leading sports app, direct-to-consumer ESPN+, leading social and digital platforms, ESPN.com, ESPN Audio, endeavors on every continent around the world, and more.About U.S. Polo Assn. and USPA GlobalU.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,200 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sportsin India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth and sport content. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.USPA Global is a subsidiary of the United States Polo Association (USPA) and manages the multi-billion-dollar sports brand, U.S. Polo Assn. USPA Global also manages the subsidiary, Global Polo, which is the worldwide leader in polo sport content. To learn more, visit globalpolo.com or Global Polo on YouTube.About the United States Polo Association® (USPA)The United States Polo Association® is organized and exists for the purposes of promoting the game of polo; coordinating the activities of its member clubs and registered player members; arranging and supervising polo tournaments, competitions, and games; and providing rules, handicaps, and tournament conditions for those events. Its overarching goals are improving the sport and promoting the safety and welfare of its human and equine participants. Founded in 1890, the USPA is the largest voluntary sports organization in North America for the sport of polo. The USPA is currently made up of more than 200 member clubs and over 5,000 registered player members. It annually awards and oversees roughly 50 national tournaments hosted by its member clubs. For more information, please visit uspolo.org.For Additional Information, Contact:Shannon Stilson - VP, Sports Marketing and MediaPhone +001.561.227.6994 - E-mail: sstilson@uspagl.comStacey Kovalsky - VP, Global PR and CommunicationsPhone +001.954.673.1331 - E-mail: skovalsky@uspagl.comChristine Calcagno - Sr. Publicist, ESPN CommunicationsPhone +001.959.216.8036 - E-mail: christine.b.calcagno@espn.comSOURCE: USPA Global Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

佛罗里达州西棕榈滩, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - USPA Global旗下娱乐子公司Global Polo延续与ESPN的深厚合作关系，继续向全球数百万家庭推广马球运动。此次具有里程碑意义的合作包括：ESPN传奇解说员克里斯·福勒将首次主持3月29日的USPA金杯赛®决赛，并连续第二年主持4月26日的美国公开马球锦标赛®决赛。赛事将在佛罗里达州棕榈滩县的USPA国家马球中心举行，届时他将与资深播音员肯尼·赖斯以及马球名人堂成员亚当·斯诺共同主持。Legendary ESPN Commentator, Chris Fowler, at the USPA National Polo Center in Palm Beach County, FloridaPhoto Credit: Alex Pacheco“我有幸报道过体育界一些最具标志性的赛事，而让我不断回归马球运动的，是马球运动员与马球马之间独特的伙伴关系，以及最高水平比赛中展现的速度与激烈程度，”福勒表示。“主持USPA金杯赛和美国公开马球锦标赛，让我能够将这项美丽运动的活力与独特性分享给更广泛的ESPN观众。”“没有什么能比得上亲眼目睹这些世界级运动员与他们的马匹伙伴在这项节奏快、充满策略的比赛中竞技的体验，”福勒补充道。USPA金杯赛始于1974年，是美国马球界仅次于美国公开马球锦标赛（始于1904年）的第二大赛事。今年的赛事将于3月4日至29日举行，届时将有10支精英队伍在最高水平的竞技中一决高下。而备受瞩目的美国公开马球锦标赛将于4月1日至26日举行，该赛事被公认为众多世界顶级球员和马匹的展示舞台，至今仍是全球最负盛名的马球赛事之一。自2004年落户佛罗里达州棕榈滩县以来，这两项赛事便一直接连举行。这些备受瞩目的马球赛事将在佛罗里达州韦灵顿的美国马球协会（USPA）国家马球中心（NPC）内的美国马球协会体育场一号场举行。4月初的USPA金杯赛决赛以及5月的美国公开马球锦标赛决赛，都将在ESPN2等ESPN旗下多个平台进行转播。具体播出时间请查阅当地节目表。“我们与ESPN的长期合作关系持续推动着马球运动、U.S. Polo Assn.品牌及其背后的全球发展势头，”管理着价值数十亿美元的全球体育品牌U.S. Polo Assn.的公司——USPA Global总裁兼首席执行官J·迈克尔·普林斯表示。“克里斯·福勒的回归以及他将同时主持USPA金杯赛和美国公开马球锦标赛的扩展参与，进一步增强了这些世界级赛事在全球观众中的势头和知名度。”“在ESPN的支持下，马球运动持续吸引着全球粉丝的关注，”普林斯补充道。除赛事直播外，ESPN平台还将播出由Global Polo制作、两度获奖的节目《Breakaway：U.S. Polo Assn.呈现》的新一季内容。观众可通过Global Polo的YouTube频道观看独家幕后花絮、球员特写及锦标赛精彩集锦，其中包括与USPA金杯赛和美国公开马球锦标赛转播相关的特别报道。“美国马球协会（USPA）很高兴看到这项运动通过与ESPN的合作持续发展，”美国马球协会（USPA）主席斯图尔特·阿姆斯特朗表示。“USPA金杯赛和美国公开马球锦标赛代表了美国赛季中USPA国家马球中心最高水平的竞技，而ESPN带来的更高曝光度，彰显了定义我们这项运动的运动精神、奉献精神和传统。”如需获取最新资讯和突发新闻，请访问 globalpolo.com 订阅《马球内幕》通讯，并浏览 uspolo.org。关于ESPN作为全球领先的多平台体育娱乐品牌，ESPN旗下拥有七家美国电视网络、领先的体育应用程序、面向消费者的流媒体服务ESPN+、领先的社交及数字平台、ESPN.com、ESPN Audio，业务遍及全球各大洲，此外还有更多业务。关于 U.S. Polo Assn. 和 USPA GlobalU.S. Polo Assn. 是美国马球协会（USPA）的官方运动品牌。USPA 成立于 1890 年，是美国规模最大的马球俱乐部和马球运动员协会。凭借数十亿美元的全球业务规模，以及通过1,200多家U.S. Polo Assn.零售店和数千个其他销售网点实现的全球分销网络，U.S. Polo Assn.为全球190多个国家的男女及儿童提供服装、配饰和鞋履。该品牌赞助了全球各大马球赛事，包括每年在棕榈滩的NPC举行的美国公开马球锦标赛®——这是美国最顶级的马球锦标赛。通过与美国ESPN、欧洲TNT和Eurosport以及印度Star Sports达成的历史性合作，由U.S. Polo Assn.赞助的数项世界顶级马球锦标赛现已实现电视转播，使全球数百万体育迷首次得以欣赏这项激动人心的运动。据《License Global》报道，U.S. Polo Assn. 一直与 NFL、PGA 巡回赛和一级方程式赛车并列，被评为全球顶级体育授权商之一。此外，这一受运动启发的品牌因全球业务增长和体育内容而屡获国际奖项。凭借其作为全球品牌的巨大成功，U.S. Polo Assn. 不仅登上了《福布斯》、《财富》、《现代零售》和《GQ》等杂志，还出现在雅虎财经和彭博社等全球众多知名媒体上。如需了解更多信息，请访问 uspoloassnglobal.com 并关注 @uspoloassn。USPA Global是美国马球协会（USPA）的子公司，负责管理价值数十亿美元的运动品牌U.S. Polo Assn.。USPA Global还管理其子公司Global Polo，后者是全球马球运动内容的领导者。如需了解更多信息，请访问globalpolo.com或YouTube上的Global Polo频道。关于美国马球协会®（USPA）美国马球协会®的成立宗旨在于推广马球运动；协调其会员俱乐部及注册球员会员的活动；组织并监督马球锦标赛、竞赛及比赛；并为相关赛事提供规则、让分制度及比赛条款。其总体目标是提升该项运动水平，并保障人类及马匹参与者的安全与福祉。USPA成立于1890年，是北美地区规模最大的马球志愿体育组织。目前，USPA拥有超过200家会员俱乐部和5,000多名注册球员会员。该协会每年主办并监督由其会员俱乐部承办的约50场全国性赛事。如需了解更多信息，请访问uspolo.org。如需更多信息，请联系：香农·斯蒂尔森（Shannon Stilson）——体育营销与媒体副总裁 电话 +001.561.227.6994 - 电子邮件：sstilson@uspagl.com斯泰西·科瓦尔斯基（Stacey Kovalsky）——全球公关与传播副总裁 电话 +001.954.673.1331 - 电子邮件：skovalsky@uspagl.com克里斯汀·卡尔卡尼奥 - ESPN传播部高级公关专员 电话 +001.959.216.8036 - 电子邮件：christine.b.calcagno@espn.com来源：USPA Global Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Mar 24, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce its annual results for the year ended 31 December 2025 (the “Year”).During the year, loss for the year was approximately RMB105.0 million, decreased by RMB80.1 million from RMB185.1 million for the year ended 31 December 2024. The Company focused on SM17 Phase 1b clinical, transformation bridging study and preparation of Phase 2 clinical trial in 2025, of which the cost was less than large scale clinical studies in 2024. As at 31 December 2025, total funding available to use was approximately RMB351.5 million, representing a significant increase compared to RMB141.4 million as at 31 December 2024. During the year, the Group gained support from well-known institutional investors including Foresight, Fullgoal, and E Fund, completed two rounds of new share subscriptions under general mandate and successfully raised an aggregate amount of approximately HK$493.7 million in net proceeds. This drove net cash flows from financing activities for the Reporting Period to approximately RMB329.4 million, providing sufficient funding to support subsequent R&D and clinical advancement.SM17 Achieves Multiple BreakthroughsSM17 is a global first-in-class humanised monoclonal antibody (mAb) targeting the receptor for IL-25, which is capable of modulating Type II allergic reaction by targeting the receptor of a critical “alarmin” molecule interleukin-25 (IL-25). The compound has the potential for treating atopic dermatitis (AD), Inflammatory Bowel Disease (IBD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF).In the field of atopic dermatitis (AD), SM17 precisely targets upstream drivers of Type 2 immune responses by blocking IL-25, a key “alarmin” cytokine, thereby suppressing the inflammatory cascade at its source. While currently approved AD therapies, including biologics, can significantly improve Eczema Area and Severity Index (EASI) scores and patients’ quality of life, current drugs under development or on the market cannot simultaneously meet the clinical needs for rapid itch relief, skin lesion recovery, and good safety profiles, indicating substantial unmet market demand. SM17’s key innovation lies in its upstream modulation of the Th2 inflammatory cytokine pathway via IL-25 receptor inhibition, thereby suppressing multiple downstream pathogenic signaling pathways. Preclinical studies have demonstrated its potential for rapid itch relief, significant skin lesion recovery, and a favorable safety profile, directly addressing the key limitations of current therapies.In April 2025, SM17 achieved encouraging positive results in a Phase 1b study in China for the treatment of moderate to severe atopic dermatitis (AD): 12-week topline data after unblinding showed that in the high dose group, 91.7% of patients achieved pruritus relief (NRS-4), 75% achieved skin healing (EASI 75), and 41.7% achieved clear or almost clear signs of AD (IGA0/1). These results significantly outperform IL-4/IL-13 monoclonal antibodies and demonstrate a significantly better safety and tolerability profile than Janus Kinase inhibitors (JAK inhibitors), making SM17 potentially the first-in-class and best-in-class therapeutics which can simultaneously achieve rapid onset of action on pruritic relief, skin healing with a good safety profile. Study results of SM17 were published in various leading international journals. Phase 2 clinical trial for AD is expected to be entered into as early as mid-2026.On 11 December 2025, an Investigational New Drug application (“IND”) for SM17 in the indication of IBD was filed with and accepted by the Center for Drug Evaluation (the “CDE”) of the National Medical Products Administration of China (“NMPA”), and the IND was subsequently approved in February 2026. This IND submission represents an important step toward expanding SM17’s therapeutic scope beyond AD to IBD, including Crohn’s disease (“CD”) and ulcerative colitis (“UC”), which are chronic, debilitating conditions with significant unmet medical needs. In October 2025, the first cohort of healthy subjects was dosed in a Phase 1 bridging clinical trial for the route of administration conversion in China. As of 31 December 2025, a total of 30 healthy subjects had been enrolled and our follow-up visits for all healthy subjects were completed in February 2026. This bridging study is expected to be completed by the second quarter of 2026. Data from this study will be leveraged to support the progression of the IBD indication directly to Phase 2 clinical development.Early-Stage Pipelines Drive Continuous Innovation GrowthIn terms of early-stage pipeline development, the Company continues to make steady progress. In June 2025, Its partner, Everest Medicines, has announced positive results from the Phase Ib/IIa clinical trial of EVER001 (SinoMab’s SN1011) for the treatment of primary membranous nephropathy (PMN), further enhancing the commercial value of the pipeline.At the same time, multiple early-stage R&D programs are progressing steadily. Anti-CGC antibody is an in-house developed, first-in-class humanised anti-γc antibody. Our in vitro assays suggested that our antibody could suppress inflammation and autoimmunity driven B, T and NK cell activation. Animal studies demonstrated that our antibody could be a potential therapeutic agent for the treatment of vitiligo, alopecia areata and possibly other autoimmune diseases through the modulation of immune cell expansion, autoreactivity and tissue infiltration. We are currently in the process of CMC optimisation and toxicology studies for our antibody and plan to submit our IND application for the treatment of alopecia areata by the fourth quarter of 2026 at the earliest.Bispecific antibody candidate is a novel, bispecific antibody targeting Receptor activator of the nuclear factor kappa-B ligand (RANKL) and sclerostin for bone-related indications. bsAb processes differential mechanisms of action tailored for the treatment of osteoporosis. Our in-house in vitro and in vivo studies demonstrated our candidate to have enhanced efficacy over market-approved antibodies such as Denosumab and Romosozumab. We are currently in the process of optimising CMC and testing toxicity in non-human primates and plan to submit our IND application by the first half of 2027 at the earliest.Expanding Strategic Partnerships and Gaining Strong Industry RecognitionsIn August 2025, the Company entered into a comprehensive strategic cooperation agreement with Sun Yat-sen University Institute of Advanced Studies Hong Kong Limited (“SYSU-IAS”). Under the cooperation agreement, the Company enjoys direct access to SYSU-IAS’s comprehensive laboratory facilities and valuable data resources, as well as access to primate and non-primate animal studies supply resources, to accelerate the development of innovative drugs and promote the translation of scientific research into clinical applications worldwide. Furthermore, the Company is actively exploring the feasibility of using artificial intelligence (AI) technology for new target identification.In January 2026, the Company was invited to participate in the J.P. Morgan Healthcare Conference, where it shared its progress in the autoimmune field with multiple multinational pharmaceutical companies (MNCs) and investors.With the support of our strong R&D capabilities, extensive pipeline assets and refined operational management, we are thrilled to obtain renowned awards during the year, including the 2nd “New Quality Productive Forces Enterprise Award” jointly presented by the Greater Bay Area Family Office Association and the Hong Kong International Family Office Association, as well as the “Most Valuable Pharmaceutical Company Award” presented by Zhitong Finance.Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, comments: "In 2025, we demonstrated the global competitiveness of our innovative pipeline with solid clinical data. The outstanding performance of SM17 in AD and its indication expansion to IBD signify our continuous transition from single-product R&D to the realisation of platform value. Looking ahead to 2026, the biopharmaceutical industry has been accelerating into the “Biotech 3.0 Era”, which is characterised by innovation-driven development, multidisciplinary integration, and intelligent processes across the entire supply chain. We are well-positioned to capture the historic opportunity of the rapid growth of out-licensing deals in China’s biopharmaceutical industry, continue to advance the clinical development of our core pipelines, and deepen our international partnership footprint. Relying on our solid cash reserves, full-spectrum capabilities across the industry chain and the principle of differentiated innovation, we strive to maximize the returns of shareholders in the long run and provide life-changing breakthrough therapies for patients.”About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies. This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeCitrus JiangWendy HuangPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年3月24日 - (亚太商讯 via SeaPRwire.com) - 中国抗体制药有限公司（"中国抗体"或"公司"，连同旗下附属公司统称"集团"，股份代号：03681.HK）欣然公布截至2025年12月31日止年度（"年内"）的全年业绩。年内，公司亏损由截至2024年12月31日止年度的人民币1.85亿元减少人民币0.80亿元至约人民币1.05亿元，主要得益于公司聚焦SM17 1b期临床、剂型桥接研究及2期临床筹备，研发成本较2024年大规模临床研究有所下降。截至2025年12月31日，公司可动用资金总额约人民币3.52亿元，较上年同期的人民币1.41亿元显著增长。年内，集团获得睿远、富国、易方达等多家知名机构投资者支持，公司完成两轮股份配售，合计募集所得款项净额约4.93亿港元，带动融资活动所得现金流净额达人民币3.29亿元，为后续研发及临床推进提供了充足资金支持。核心产品SM17取得多项突破性进展SM17是全球首创（First-in-Class）的靶向IL-25受体的人源化单抗，通过靶向II型免疫核心"警戒素（Alarmin）"分子白细胞介素25（IL-25）受体，调节II型炎症反应。SM17具有治疗特应性皮炎（AD）、炎症性肠病（IBD）、哮喘、慢性鼻窦炎伴鼻息肉（CRSwNP）及特发性肺纤维化（IPF）的潜力。在特应性皮炎（AD）领域，SM17精准作用于II型免疫反应的上游，通过阻断被称作"警报素"的关键细胞因子IL-25，从源头上抑制导致AD的炎症级联反应。当前，已获批上市的AD疗法（包括生物制剂）虽然可以大大改善患者的湿疹面积和严重程度指数以及生活质量。然而目前在研在售药物无法同时满足快速起效止痒，皮损恢复，同时具备良好安全性的临床需求，市场尚存在巨大空间。SM17的创新之处在于，它通过靶向Th2炎性细胞因子通路上游（如IL-25受体），从而对下游信号通路的致病因子产生抑制效果，且在临床前研究中展现出快速止痒、显著修复皮损以及良好安全性的潜力，直击现有疗法痛点。2025年4月，SM17在中国治疗中重度特应性皮炎的1b期研究中，取得了令人鼓舞的积极结果：揭盲后的12周顶线数据显示，高剂量组的91.7%的患者实现瘙痒缓解指标（NRS-4），75%达到皮损恢复(EASI75)指标，41.7%达到完全或近乎完全清除AD症状指标（IGA 0/1）。该结果显著优于IL4/IL-13类单抗药物且安全性与耐受性显著优于Janus激酶抑制剂（JAK抑制剂），这使得SM17有望成为一款可同时实现快速止痒、皮肤损伤修复，且安全性表现优异的同类首创及同类最优疗法。SM17的研究成果已在多家国际顶级期刊发表。预计最早在2026年年中进入AD的2期临床试验。此外，SM17持续拓展出多个新的适应症，于本年度第二季度，SM17的适应症拓展进一步取得突破性进展。2025年12月11日，SM17用于治疗IBD的新药研究申请（"IND"）已提交予中国国家药品监督管理局（"中国国家药监局"）药品审评中心（"药品审评中心"），并已获受理，且IND随后于2026年2月获批。此次IND的提交，代表着SM17治疗范围从AD拓展至IBD的重要里程碑，涵盖克罗恩病（"CD"）及溃疡性结肠炎（"UC"）等慢性、衰竭性疾病，这些疾病存在显著未满足的医疗需求。于2025年10月，首组健康受试者已在中国给药途径转换之1期桥接临床研究中给药。截至2025年12月31日，合共三十名健康受试者已入组且对全部健康受试者之随访于2026年2月完成。该桥接研究预期于2026年第二季度前完成。该研究数据将用作支持IBD适应症的进展直接推进2期临床开发。早期在研管线布局提供持续创新动力在早期在研管线方面，公司持续取得积极进展。2025年6月合作伙伴云顶新耀公布了EVER001（中国抗体SN1011）用于治疗原发性膜性肾病（PMN）的1b/2a期临床试验的积极结果，进一步提升了管线的商业化价值。同时，公司多项早期研发项目稳步推进。其中，抗CGC抗体是一款内部开发的全球首创人源化抗γc抗体。动物研究显示，该抗体可能透过调节免疫细胞的扩增、自身反应性及组织浸润，成为治疗白癜风、斑秃，甚至其他自身免疫性疾病的潜在治疗药物。目前正在针对该抗体进行CMC优化及毒理学研究，并计划最早在2026年第四季度前提交其治疗斑秃的IND申请。双特异性抗体候选药物是一种新型双特异性抗体，靶向核因子kappa-B配体受体激活因子(RANKL)及骨硬化蛋白，治疗骨相关适应症。通过的内部体外及体内研究显示，相较于市售批准的抗体（如地诺单抗及罗莫珠单抗），该候选药物展现出更佳的疗效。目前正在进行CMC优化，并在非人灵长类动物中测试其毒性，并计划最早在2027年上半年前提交IND申请。协同推进战略合作与BD授权，荣获多项重磅荣誉公司于2025年8月与中山大学香港高等研究院有限公司（"SYSU-IAS"）签订全面战略合作协议，本公司可直接使用SYSUIAS完备的实验室设施与宝贵的数据资源，并获得包括灵长类及非灵长类实验动物在内的科研资源支持，加速创新药物研发进程，推动科研成果在全球范围内向临床应用转化。同时公司正积极探索运用人工智能(AI)技术开展新靶点发现的可行性。2026年1月，公司受邀参加摩根大通医疗健康大会（JPM大会）并与多家MNC、投资者分享了公司在自免领域的进展。依托雄厚的研发实力、丰富的管线储备及精细化运营管理，公司于本年度荣获多项重磅荣誉，包括粤港澳大湾区家族办公室协会与香港国际家族办公室协会联合颁发的第二届"新质生产力企业大奖"，以及智通财经授予的"最具价值医药公司奖"。中国抗体董事长、执行董事兼首席执行官梁瑞安博士表示："2025年，我们凭借扎实的临床数据证明了创新管线的全球竞争力，SM17在AD中的优异表现及其向IBD的拓展，标志着我们正从单一产品研发迈向平台价值的持续兑现。展望2026年，生物医药行业正加速迈入‘生物技术3.0时代’，创新驱动、多学科融合及全产业链智能化将成为核心发展方向。我们将把握中国生物医药对外授权高速增长的历史机遇，持续推进核心管线的临床开发，深化国际合作布局。依托坚实的现金储备、完善的产业链能力以及差异化创新优势，为股东创造长期价值，并为患者提供具有突破性的治疗方案。"关于中国抗体制药有限公司中国抗体制药有限公司（股份代号：03681.HK）是首创新药及潜在同类最佳抗体药物研发领域的开拓者，专注于自身免疫性疾病、以及由此导致的神经系统疾病及其他难治的耗损性疾病，致力于解决未被满足的医疗需求。中国抗体始终致力于开发针对全新靶点及通过创新机制的治疗性抗体，旨在现有疗法效果不佳的领域实现差异化临床成果。其丰富的研发管线包括：SM17在AD治疗中展现出卓越的止痒效果、皮肤清除率及安全性，同时在哮喘和特发性肺纤维化（IPF）领域具有应用潜力；其旗舰抗CD22舒西利单抗，除了临床验证对类风湿关节炎（RA）具有临床疗效外，目前正针对系统性红斑狼疮（SLE）和阿尔茨海默病开展临床评估；另一款抗CGC（共同γ链）创新单抗，正准备进入治疗斑秃和白癜风的临床研究；中国抗体亦研发了一款能同时刺激骨骼生长及抑制骨骼流失、治疗骨质疏松症的双特异性抗体。中国抗体以突破性疗效为核心追求，不断重新定义患者护理标准，稳居突破性疗法领域的领军地位。此新闻稿由真灼财经代中国抗体制药有限公司发布投资者及媒体查询联络人：Bunny LeeCitrus JiangWendy Huang电话：（852）5316 9995电邮：ir_sinomab@zhenzhuoglobal.com Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com